PT101722A - Formulacoes de analogo de insuluna - Google Patents

Formulacoes de analogo de insuluna

Info

Publication number
PT101722A
PT101722A PT101722A PT10172295A PT101722A PT 101722 A PT101722 A PT 101722A PT 101722 A PT101722 A PT 101722A PT 10172295 A PT10172295 A PT 10172295A PT 101722 A PT101722 A PT 101722A
Authority
PT
Portugal
Prior art keywords
insuluna
analog formulations
formulations
analog
insuluna analog
Prior art date
Application number
PT101722A
Other languages
English (en)
Other versions
PT101722B (pt
Inventor
Bruce Hill Frank
David Nettleship Brems
Diane Lee Bakaysa
Henry Acken Havel
Allen Howard Pekar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT101722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT101722A publication Critical patent/PT101722A/pt
Publication of PT101722B publication Critical patent/PT101722B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT101722A 1994-06-16 1995-06-14 Formulacoes de analogo de insuluna PT101722B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
PT101722A true PT101722A (pt) 1995-12-29
PT101722B PT101722B (pt) 1997-02-28

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101722A PT101722B (pt) 1994-06-16 1995-06-14 Formulacoes de analogo de insuluna

Country Status (39)

Country Link
US (1) US5474978A (pt)
JP (2) JP3171541B2 (pt)
KR (1) KR100382326B1 (pt)
CN (1) CN1105576C (pt)
AT (1) AT408720B (pt)
BE (1) BE1009408A5 (pt)
BR (1) BR9502795A (pt)
CA (1) CA2151560C (pt)
CH (2) CH689250A5 (pt)
CO (1) CO4410203A1 (pt)
CZ (1) CZ287484B6 (pt)
DE (1) DE19521720B4 (pt)
DK (1) DK173015B1 (pt)
ES (1) ES2091727B1 (pt)
FI (1) FI118207B (pt)
FR (2) FR2721214B1 (pt)
GB (1) GB2291427B (pt)
GR (1) GR1003004B (pt)
HK (1) HK1015138A1 (pt)
HU (1) HU227240B1 (pt)
IE (1) IE68853B1 (pt)
IL (1) IL114151A (pt)
IT (1) IT1276723B1 (pt)
LU (1) LU88626A1 (pt)
MY (1) MY115631A (pt)
NL (1) NL1000566C2 (pt)
NO (1) NO322128B1 (pt)
NZ (1) NZ272359A (pt)
PE (1) PE19496A1 (pt)
PL (1) PL181310B1 (pt)
PT (1) PT101722B (pt)
RO (1) RO113530B1 (pt)
RS (1) RS49577B (pt)
RU (1) RU2152399C2 (pt)
SE (1) SE509052C2 (pt)
SI (1) SI9500200A (pt)
TW (1) TW421596B (pt)
UA (1) UA26874C2 (pt)
ZA (1) ZA954943B (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US6274549B1 (en) * 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes
CZ297937B6 (cs) * 1996-06-20 2007-05-02 Novo Nordisk A/S Vodný inzulínový prípravek obsahující chlorid sodný, zpusob a pouzití
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
EP1121145B1 (en) * 1998-10-16 2002-04-17 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
WO2000029013A1 (en) * 1998-11-18 2000-05-25 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
EP1383540B1 (en) * 2000-07-31 2009-04-29 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
DK1633876T3 (da) 2003-06-17 2008-12-08 Sembiosys Genetics Inc Fremgangsmåde til fremstilling af insulin i planter
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
CA2563681C (en) 2004-05-06 2015-11-03 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
BRPI0510221A (pt) * 2004-05-14 2007-10-23 Emisphere Tech Inc composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP2926828B1 (en) * 2004-10-05 2019-12-11 Novo Nordisk A/S A pharmaceutical formulation
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
NZ566083A (en) 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
US8026392B2 (en) * 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (en) * 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2008116141A1 (en) * 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
JP5555634B2 (ja) 2007-11-02 2014-07-23 エミスフェア テクノロジーズ インコーポレイティッド ビタミンｂ１２欠乏症を治療するための方法
RU2555557C2 (ru) 2008-07-31 2015-07-10 Кейз Вестерн Ризев Юнивесити Инсулин, стабилизированный галогеном
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
US9050370B2 (en) 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
RU2011137413A (ru) 2009-02-12 2013-03-20 Проекто Де Биомедисина Сима, С.Л. Применение кардиотрофина-1 для лечения метаболических заболеваний
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
KR20140009163A (ko) 2010-09-30 2014-01-22 솔베이(소시에떼아노님) 천연유래 에피클로로히드린의 유도체
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
US10159735B2 (en) * 2012-06-26 2018-12-25 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (en) 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2015006997A (es) 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
JOP20190277B1 (ar) 2017-06-01 2023-09-17 Lilly Co Eli تركيبات إنسولين سريعة المفعول
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
KR20220115927A (ko) 2019-10-25 2022-08-19 세르카코르 래버러토리즈, 인크. 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
WO1990001038A1 (en) * 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DE122006000017I1 (de) * 1993-06-21 2006-06-29 Novo Nordisk As ASP-B28-Insulinkristalle
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
CH689250A5 (de) 1999-01-15
NL1000566A1 (nl) 1995-12-18
HU227240B1 (en) 2010-12-28
IT1276723B1 (it) 1997-11-03
GR950100229A (en) 1996-02-29
HU9501716D0 (en) 1995-08-28
BE1009408A5 (fr) 1997-03-04
FI118207B (fi) 2007-08-31
GB9512038D0 (en) 1995-08-09
ATA101695A (de) 2001-07-15
RO113530B1 (ro) 1998-08-28
KR960000924A (ko) 1996-01-25
ITMI951278A1 (it) 1996-12-14
PL309098A1 (en) 1995-12-27
GR1003004B (el) 1998-11-05
HK1015138A1 (en) 1999-10-08
CH689935A5 (de) 2000-02-15
IE950436A1 (en) 1995-12-27
YU39695A (sh) 1997-08-22
JP3171541B2 (ja) 2001-05-28
FR2741078A1 (fr) 1997-05-16
DE19521720A1 (de) 1995-12-21
CA2151560A1 (en) 1995-12-17
RU95110109A (ru) 1997-05-10
CN1105576C (zh) 2003-04-16
BR9502795A (pt) 1996-03-12
RS49577B (sr) 2007-04-10
ES2091727A1 (es) 1996-11-01
DE19521720B4 (de) 2009-09-03
IE68853B1 (en) 1996-07-24
CO4410203A1 (es) 1997-01-09
PL181310B1 (pl) 2001-07-31
AU694501B2 (en) 1998-07-23
RU2152399C2 (ru) 2000-07-10
US5474978A (en) 1995-12-12
FR2721214B1 (fr) 1997-09-26
AT408720B (de) 2002-02-25
CA2151560C (en) 2000-05-09
PT101722B (pt) 1997-02-28
SE509052C2 (sv) 1998-11-30
PE19496A1 (es) 1996-06-01
FR2721214A1 (fr) 1995-12-22
LU88626A1 (fr) 1996-02-01
MY115631A (en) 2003-08-30
SE9502167D0 (sv) 1995-06-14
ZA954943B (en) 1997-09-14
AU2168095A (en) 1996-01-04
KR100382326B1 (ko) 2003-07-07
HUT73186A (en) 1996-06-28
CZ287484B6 (en) 2000-12-13
CN1122248A (zh) 1996-05-15
SE9502167L (sv) 1995-12-17
JP2001199899A (ja) 2001-07-24
NO322128B1 (no) 2006-08-21
DK67795A (da) 1995-12-17
ES2091727B1 (es) 1998-02-01
JPH083067A (ja) 1996-01-09
NO952357D0 (no) 1995-06-14
IL114151A (en) 2000-09-28
GB2291427A (en) 1996-01-24
NO952357L (no) 1995-12-18
FR2741078B1 (fr) 1998-08-07
IL114151A0 (en) 1995-10-31
NL1000566C2 (nl) 1996-12-03
FI952931A0 (fi) 1995-06-14
SI9500200A (en) 1996-02-29
GB2291427B (en) 1998-09-16
DK173015B1 (da) 1999-11-15
ITMI951278A0 (it) 1995-06-14
CZ154295A3 (en) 1996-02-14
FI952931A (fi) 1995-12-17
UA26874C2 (uk) 1999-12-29
TW421596B (en) 2001-02-11
NZ272359A (en) 1996-10-28

Similar Documents

Publication Publication Date Title
PT101722A (pt) Formulacoes de analogo de insuluna
EE9700138A (et) Aerosoolravimvormid
DE69526966T2 (de) Hautkräftigende kometische zusammensetzung
MA24473A1 (fr) Formulations
FI954773A0 (fi) Antihypertriglyserideeminen koostumus
DE69522250T2 (de) Deodorant
ITMI951395A0 (it) Formulazioni di f-silicone
ID16781A (id) Formulasi-formulasi farmasi
DE69521906D1 (de) Zahnhygiene - präparate
ITMI941169A0 (it) Formulazioni farmaceutiche
ITMI940362A0 (it) Composizione antitosse
BR9509899A (pt) Composição modificadora de sabor
ID18698A (id) Komposisi farmasi
MA23731A1 (fr) Compositions detegentes
ATA194094A (de) Artikulator
ITMI962628A0 (it) Composizione farmaceutica
NO970747D0 (no) Sammensetninger
NO991430D0 (no) Insektfordrivende formuleringer
DK60694A (da) Liftophængt redskab
FI970667A0 (fi) Koostumukset
SE9404469D0 (sv) Aerosol formulations
SE9404467D0 (sv) Drug formulations
KR960018409U (ko) 아날로그 메터기
PT9344T (pt) Cadeira de rodas
KR960000400U (ko) 주걱꽂이 겸용 계량컵

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19951006

FG3A Patent granted, date of granting

Effective date: 19961120

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20150615